Global Erythropoietin Stimulating Agents Market By Product Type (Epoetin-Alfa, Epoetin-Beta, Epoetin-Delta, Epoetin-Omega, Darbepoetin-Alfa, Others), By Application (Oncology, Renal Disorders, Anemia, Surgeries, Others), By Distribution Channel (Hospital Pharmacies, retail Pharmacies, Online Pharmacies), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Erythropoietin Stimulating Agents Market size was valued at USD 8.930 million in 2022 and is expected to reach USD 15.909 million by 2029, at a CAGR of 8.6% during the forecast period 2023-2029. Erythropoietin is a hormone produced by kidney that enables stimulate production of RBC. Erythropoietin stimulating agents are the drugs used to stimulate the bone marrow to enhance the production of red blood cells. The drugs are commonly used in the treatment of anemia due to end stage renal disease (ESRD), major surgeries, chemotherapy, and HIV/AIDS leads to decrease the need of blood transfusion. Erythropoiesis is the name given to the process of red blood cell production. Erythropoiesis is a process that occurs in the bone marrow. Erythropoiesis-stimulating agents are substances that promote the production of red blood cells. These are recombinant versions of the hormone erythropoietin, which is produced naturally by the kidneys and is responsible for promoting red blood cell formation in the bone marrow. For the treatment of anaemia, erythropoiesis-stimulating drugs are indicated. Hemoglobin is a protein found in red blood cells that transports oxygen throughout the body. Anemia occurs when the body does not obtain enough oxygen due to a low number of red blood cells. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Erythropoietin Stimulating Agents Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Erythropoietin Stimulating Agents Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

 

Erythropoietin Stimulating Agents Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.6%

Largest Market

Asia-Pacific

Fastest Growing Market

Europe
Erythropoietin Stimulating Agents Market Dynamics

The global market for erythropoiesis-stimulating drugs is growing due to the rising frequency of anaemia cases around the world. Furthermore, increased knowledge of erythropoiesis-stimulating agent therapy is fueling market expansion. Because of the expanding prevalence of chronic kidney disease and cancer, as well as the growing desire for less expensive erythropoietin medications, the demand for erythropoiesis-stimulating substances is fast increasing. Researchers and pharmaceutical companies are working to produce new erythropoietin medicines. However, strict regulatory criteria and side effects associated with erythropoiesis-stimulating drugs, such as hypersensitivity, hypertension, seizures, or convulsions, are limiting market expansion. Rise in prevalence of anemia, ESRD, HIV, and cancer around the globe is witnessed to increased demand for global erythropoietin stimulating agents market. Moreover, rise in R&D for innovation of newer drugs, entry of bio-similar and generics into market due to expiration of patents are expected to increase in the adoption of low-cost drugs in developing countries, and rise in awareness about the benefits erythropoietin drugs are anticipated to propel the erythropoietin stimulating agents market over the forecast period. However, stringent regulations for the product approval, adverse effects associated with drugs, and high cost of patented drugs are impede the growth of erythropoietin stimulating agents market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Erythropoietin Stimulating Agents Market Segmentation

By Product Type
  • Epoetin-Alfa
  • Epoetin-Beta
  • Epoetin-Delta
  • Epoetin-Omega
  • Darbepoetin-Alfa
  • Others
By Application
  • Oncology
  • Renal Disorders
  • Anemia
  • Surgeries
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

Erythropoietin Stimulating Agents Market size was valued at USD 8.930 million in 2022 and is expected to reach USD 15.909 million by 2029.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

rising frequency of anaemia cases around the world

Europe is the fastest-growing for erythropoietin stimulating agents market

1.Executive Summary
2.Global Erythropoietin Stimulating Agents Market Introduction 
2.1.Global Erythropoietin Stimulating Agents Market  - Taxonomy
2.2.Global Erythropoietin Stimulating Agents Market  - Definitions
2.2.1.Product Type
2.2.2.Application
2.2.3.Distribution Channel
2.2.4.Region
3.Global Erythropoietin Stimulating Agents Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Erythropoietin Stimulating Agents Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Erythropoietin Stimulating Agents Market  By Product Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Epoetin-Alfa
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Epoetin-Beta
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Epoetin-Delta
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Epoetin-Omega
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Darbepoetin-Alfa
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6.Global Erythropoietin Stimulating Agents Market  By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Oncology
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Renal Disorders
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Anemia
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Surgeries
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Erythropoietin Stimulating Agents Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Erythropoietin Stimulating Agents Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Epoetin-Alfa
9.1.2.Epoetin-Beta
9.1.3.Epoetin-Delta
9.1.4.Epoetin-Omega
9.1.5.Darbepoetin-Alfa
9.1.6.Others
9.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oncology
9.2.2.Renal Disorders
9.2.3.Anemia
9.2.4.Surgeries
9.2.5.Others
9.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Epoetin-Alfa
10.1.2.Epoetin-Beta
10.1.3.Epoetin-Delta
10.1.4.Epoetin-Omega
10.1.5.Darbepoetin-Alfa
10.1.6.Others
10.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oncology
10.2.2.Renal Disorders
10.2.3.Anemia
10.2.4.Surgeries
10.2.5.Others
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Epoetin-Alfa
11.1.2.Epoetin-Beta
11.1.3.Epoetin-Delta
11.1.4.Epoetin-Omega
11.1.5.Darbepoetin-Alfa
11.1.6.Others
11.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oncology
11.2.2.Renal Disorders
11.2.3.Anemia
11.2.4.Surgeries
11.2.5.Others
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Epoetin-Alfa
12.1.2.Epoetin-Beta
12.1.3.Epoetin-Delta
12.1.4.Epoetin-Omega
12.1.5.Darbepoetin-Alfa
12.1.6.Others
12.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oncology
12.2.2.Renal Disorders
12.2.3.Anemia
12.2.4.Surgeries
12.2.5.Others
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Erythropoietin Stimulating Agents Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Epoetin-Alfa
13.1.2.Epoetin-Beta
13.1.3.Epoetin-Delta
13.1.4.Epoetin-Omega
13.1.5.Darbepoetin-Alfa
13.1.6.Others
13.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oncology
13.2.2.Renal Disorders
13.2.3.Anemia
13.2.4.Surgeries
13.2.5.Others
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Teva Pharmaceutical Industries Ltd. (Israel)
14.2.2.Biocon Limited (India)
14.2.3.Celltrion, Inc. (South Korea)
14.2.4.Hoffmann La Roche, Ltd. (Switzerland)
14.2.5.Hospira, Inc. (Pfizer, Inc.) (U.S.)
14.2.6.Johnson & Johnson Services, Inc. (U.S.)
14.2.7.Amgen, Inc. (U.S.)
14.2.8.Dr. Reddy's Laboratories Ltd (India)
14.2.9.Intas Pharmaceuticals (India)
14.2.10.3SBio, Inc. (China)
14.2.11.Kissei Pharmaceuticals Ltd (Japan)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Biocon Limited (India)
  • Celltrion, Inc. (South Korea)
  • Hoffmann La Roche, Ltd. (Switzerland)
  • Hospira, Inc. (Pfizer, Inc.) (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Amgen, Inc. (U.S.)
  • Dr. Reddy's Laboratories Ltd (India)
  • Intas Pharmaceuticals (India)
  • 3SBio, Inc. (China)
  • Kissei Pharmaceuticals Ltd (Japan)

Adjacent Markets